Transfusion Medicine, Volume 36, Issue 5, Page 503-510, October 2026.Abstract Background Since the COVID‐19 pandemic, demand for blood products has remained high, while donations have declined. Institutional policies guiding the use of these products may affect their availability, utilisation and waste. We surveyed blood banks (BBs) in the United States (U.S.) to assess policies and practices related to cryoprecipitate ...
Chinelo P. Onyenekwu +3 more
wiley +1 more source
Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany. [PDF]
Pharmacoecon OpenMeier N +5 more
europepmc +1 more source
Correction to: Nonacog Beta Pegol: A Review in Haemophilia B. [PDF]
Drugs, 2018 Syed YY.
europepmc +1 more source
Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP. [PDF]
Haemophilia, 2019 von Mackensen S +3 more
europepmc +1 more source
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis. [PDF]
Adv Ther, 2020 Hermans C +7 more
europepmc +1 more source
Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B. [PDF]
Haemophilia, 2019 Fukutake K +6 more
europepmc +1 more source
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. [PDF]
Haemophilia, 2020 Shapiro A +8 more
europepmc +1 more source
Intraventricular haemorrhage and obstructive hydrocephalus in a term neonate: an uncommon presentation of haemophilia B. [PDF]
BMJ Case Rep, 2018 Bhattacharya D, Sharawat IK, Saini L.
europepmc +1 more source
Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa. [PDF]
Blood Coagul Fibrinolysis, 2018 Rendo P +4 more
europepmc +1 more source